Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Preferred Dividend Payments (2023 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Preferred Dividend Payments for 3 consecutive years, with $901996.0 as the latest value for Q4 2025.

  • On a quarterly basis, Preferred Dividend Payments rose 103.17% to $901996.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $901996.0, a 89.33% decrease, with the full-year FY2025 number at $1.1 million, down 92.5% from a year prior.
  • Preferred Dividend Payments was $901996.0 for Q4 2025 at PharmaCyte Biotech, up from $443958.0 in the prior quarter.
  • In the past five years, Preferred Dividend Payments ranged from a high of $4.5 million in Q4 2023 to a low of $443958.0 in Q4 2024.
  • A 3-year average of $2.4 million and a median of $3.1 million in 2024 define the central range for Preferred Dividend Payments.
  • Peak YoY movement for Preferred Dividend Payments: crashed 90.05% in 2024, then surged 103.17% in 2025.
  • PharmaCyte Biotech's Preferred Dividend Payments stood at $4.5 million in 2023, then plummeted by 90.05% to $443958.0 in 2024, then soared by 103.17% to $901996.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Preferred Dividend Payments are $901996.0 (Q4 2025), $443958.0 (Q4 2024), and $685801.0 (Q3 2024).